|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AC19
|
|
gptkbp:brand
|
gptkb:Enspryng
|
|
gptkbp:CASNumber
|
1353551-71-3
|
|
gptkbp:developer
|
gptkb:Roche
gptkb:Chugai_Pharmaceutical
|
|
gptkbp:drugClass
|
immunosuppressant
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
30 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
satralizumab
|
|
gptkbp:indication
|
gptkb:neuromyelitis_optica_spectrum_disorder
gptkb:neuromyelitis_optica
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
humanized monoclonal antibody
|
|
gptkbp:mechanismOfAction
|
inhibits IL-6 signaling
|
|
gptkbp:molecularWeight
|
~146 kDa
|
|
gptkbp:pregnancyCategory
|
unknown
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
fatigue
headache
injection site reaction
rash
arthralgia
|
|
gptkbp:target
|
gptkb:interleukin-6_receptor
|
|
gptkbp:UNII
|
6QY1D9Y4F1
|
|
gptkbp:usedFor
|
gptkb:neuromyelitis_optica_spectrum_disorder
|
|
gptkbp:bfsParent
|
gptkb:Enspryng
|
|
gptkbp:bfsLayer
|
8
|